Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina, USA.
Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
J Clin Invest. 2021 Aug 16;131(16). doi: 10.1172/JCI143119.
PFKP (phosphofructokinase, platelet), the major isoform of PFK1 expressed in T cell acute lymphoblastic leukemia (T-ALL), is predominantly expressed in the cytoplasm to carry out its glycolytic function. Our study showed that PFKP is a nucleocytoplasmic shuttling protein with functional nuclear export and nuclear localization sequences (NLSs). Cyclin D3/CDK6 facilitated PFKP nuclear translocation by dimerization and by exposing the NLS of PFKP to induce the interaction between PFKP and importin 9. Nuclear PFKP stimulated the expression of C-X-C chemokine receptor type 4 (CXCR4), a chemokine receptor regulating leukemia homing/infiltration, to promote T-ALL cell invasion, which depended on the activity of c-Myc. In vivo experiments showed that nuclear PFKP promoted leukemia homing/infiltration into the bone marrow, spleen, and liver, which could be blocked with CXCR4 antagonists. Immunohistochemical staining of tissues from a clinically well-annotated cohort of T cell lymphoma/leukemia patients showed nuclear PFKP localization in invasive cancers, but not in nonmalignant T lymph node or reactive hyperplasia. The presence of nuclear PFKP in these specimens correlated with poor survival in patients with T cell malignancy, suggesting the potential utility of nuclear PFKP as a diagnostic marker.
PFKP(磷酸果糖激酶,血小板)是 T 细胞急性淋巴细胞白血病(T-ALL)中表达的 PFK1 的主要同工型,主要表达在细胞质中以执行其糖酵解功能。我们的研究表明,PFKP 是一种具有核输出和核定位序列(NLS)功能的核质穿梭蛋白。Cyclin D3/CDK6 通过二聚化和暴露 PFKP 的 NLS 促进 PFKP 核易位,从而诱导 PFKP 与 importin 9 之间的相互作用。核 PFKP 刺激 C-X-C 趋化因子受体 4(CXCR4)的表达,CXCR4 是调节白血病归巢/浸润的趋化因子受体,从而促进 T-ALL 细胞侵袭,这取决于 c-Myc 的活性。体内实验表明,核 PFKP 促进白血病归巢/浸润到骨髓、脾脏和肝脏,这可以用 CXCR4 拮抗剂阻断。对一组临床注释良好的 T 细胞淋巴瘤/白血病患者组织的免疫组织化学染色显示,侵袭性癌症中有核 PFKP 定位,但非恶性 T 淋巴结或反应性增生中没有。这些标本中存在核 PFKP 与 T 细胞恶性肿瘤患者的不良生存相关,表明核 PFKP 作为诊断标志物具有潜在的应用价值。